Quantcast

Latest Fenofibrate Stories

2014-09-21 23:01:43

LifeScienceIndustryResearch.com adds Latest Report on “Market Research Report on Global and Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019” to its store. Inquire Before Buying at http://www.lifescienceindustryresearch.com/inquire-before-buying?rname=12380 Dallas, TX (PRWEB) September 21, 2014 Market Research Report on Global and Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Fenofibrate (CAS...

Fenofibrate for diabetic women
2014-08-21 03:00:45

Dan Gafney, University of Sydney The cholesterol-lowering drug fenofibrate cuts cardiovascular disease risks by 30 percent in women with type-2 diabetes, a new University of Sydney study reveals. "The finding is good news for women," says the study's chairman, University of Sydney Professor, Tony Keech. "The study shows that fenofibrate reduced the risk of dying from cardiovascular disease, or having a stroke or other adverse cardiovascular event by 30 percent in women and 13 percent...

2014-06-16 09:46:15

American Diabetes Association Panelists will argue pros and cons at symposium New guidelines for the treatment of high cholesterol are not appropriate for people with type 2 diabetes – or are they? Two researchers will debate the topic at a symposium to be held on Tuesday, June 17, at the American Diabetes Association's 74th Scientific Sessions®. At issue are the newest guidelines issued jointly by the American College of Cardiology and American Heart Association in November...

2014-06-03 12:40:05

MONTGOMERY, Ala., June 3, 2014 /PRNewswire/ -- H2-Pharma, LLC announced today the launch of Fenofibrate 50 mg and 150 mg capsules, an authorized generic version of LIPOFEN®. LIPOFEN® is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and to increase high-density lipoprotein cholesterol in adult patients with primary hypercholesterolemia or mixed dyslipidemia. "We are pleased to introduce this...

2014-05-02 08:25:43

Data suggest lower risk of major adverse cardiovascular events and death, especially in patients with diabetes or prior coronary heart disease ORLANDO, Fla., May 2, 2014 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced data suggesting that the use of a target low-density lipoprotein...

2014-04-11 12:00:31

Atrasentan reduces blood pressure, cholesterol, and urinary protein excretion A drug called atrasentan provides health benefits for patients who have both diabetes and kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings suggest that atrasentan may help maintain the well-being of many patients who are at high risk of experiencing serious medical problems. Individuals with type 2 diabetes have a high...

2014-03-27 04:20:44

Companies to Host Investor Conference Call on Alirocumab on March 31 at 9 AM EDT PARIS and TARRYTOWN, N.Y., March 27, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from alirocumab clinical studies will be presented at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, D.C. March 29-31. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein...

2014-02-05 11:24:51

An educational toolkit designed to improve care of patients with diabetes was not effective, Baiju R Shah and colleagues (University of Toronto) found in a cluster randomized trial conducted in 2009-2011. During 10 months of follow-up, patients of Canadian family physicians who had been cluster-randomized to receive the toolkit did not receive improved care and their outcomes did not differ compared with patients of physicians who did not receive the toolkit. All 933,789 people aged ≥40...

2014-02-04 11:23:37

Intensive blood pressure and cholesterol lowering was not associated with reduced risk for diabetes-related cognitive decline in older patients with long-standing type 2 diabetes mellitus, according to a study by Jeff D. Williamson, M.D., M.H.S., of the Wake Forest School of Medicine, Winston-Salem, N.C., and colleagues. Patients with type 2 diabetes (T2DM) are at increased risk for decline in cognitive function, for reduced brain volume and increased white matter lesions on brain imaging,...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'